JaLCDOI 10.18926/AMO/32723
FullText URL fulltext.pdf
Author Irino, Shozo| Tanji, Tameyo| Uno, Junichiro| Oka, Akira|
Abstract <p>By injecting 131I-Lipiodol into lymphatics of the dorsum of dog feet, the distribution of 13JI in the lymph nodes and other principal organs as well as its histological effect were studied periodically after the injection for the period of two months. The characteristic feature of J3JI distribution was the fact that J31I was accumulated into lymph nodes markedly higher than in any other organs and it was retained there over a long period of time. Histological examinations of the lymph nodes revealed a marked lymphocytopenia, the loss of germinal center, practically complete loss of lymphoid elements already 5 days after injection, and marked fibrosis. In the lung a considerable J3JI·distribution could be seen in early stage:, but with lapse of time it decreased rapidly. The distribution in other organs such as liver, spleen, bone marrow, kidney, ureter, bladder, thyroid gland, pancreas, testicles and small and large intestines was negligible in amount, and any specific histologic effect of irradiation could not be recognized in these organs including the lung. From these results, the authors concluded that 131I-Lipiodol has a selective activity on lymph nodes by injecting it via lymphatics and it is a safe method in clinical application to treat the patients bearing malignant lymphoma or metastatic lymph nodes.</p>
Amo Type Article
Published Date 1974-02
Publication Title Acta Medica Okayama
Volume volume28
Issue issue1
Publisher Okayama University Medical School
Start Page 59
End Page 67
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 4366051
NAID 120002311696
JaLCDOI 10.18926/AMO/32706
FullText URL fulltext.pdf
Author Irino, Shozo| Tanji, Tameyo| Uno, Junichiro| Oka, Akira|
Abstract <p>By endolymphatic injection of radioisotope 131I.Lipiodol, so.called endolymphatic radiotherapy, we treated 10 cases with malignant lymphoma and found a marked tumor reduction to normal size in all the 10 cases we tried. It seems that this method is one of the most effective therapeutic methods for malignant lymphoma, espe. cially invading into the retroperitoneal lymph nodes.</p>
Amo Type Article
Published Date 1974-04
Publication Title Acta Medica Okayama
Volume volume28
Issue issue2
Publisher Okayama University Medical School
Start Page 111
End Page 118
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 4368508
NAID 120002311489
JaLCDOI 10.18926/AMO/32062
FullText URL fulltext.pdf
Author Tanaka, Toshio| Sezaki, Tatsuo| Hujita, Mineji| Oka, Akira| Okamoto, Tsukasa| Ito, Jishu|
Abstract <p>A total of 45 cases of multiple myeloma has been followed up clinically during the period from 7 to 80 months. Out of these, six patients (13.3%) were diagnosed to be the tumor-forming type; they developed discrete tumor formation at the disease onset or during clinical observation. Biological behavior of these cases is briefly outlined. Histologically, five cases presented with well or moderately well differentiated plasma cells according to the grading made by Pasmantier and Azar. The remaining one case was poorly differentiated in cell maturity, and with electron and immunofluorescence microscopies, proved to be of plasmacytic nature.</p>
Keywords tomor-forming tupe multiple myeloma
Amo Type Article
Published Date 1979-10
Publication Title Acta Medica Okayama
Volume volume33
Issue issue5
Publisher Okayama University Medical School
Start Page 359
End Page 370
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 160183
JaLCDOI 10.18926/AMO/30703
FullText URL fulltext.pdf
Author Ohnoshi, Taisuke| Oka, Akira| Hayashi, Kyoichi| Ueoka, Hiroshi| Sato, Masaharu| Nishihara, Ryuji| Yasuoka, Masatoshi| Sando, Yasuhiro| Tanaka, Toshio| Kimura, Ikuro|
Abstract <p>Eighteen patients with advanced non-Hodgkin's lymphoma other than the diffuse histiocytic type were treated with a combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP). The objective response rate was 83% (15/18); 61% (11/18) achieved complete remission. The median duration of complete remission was 11 months ranging from 2 to 39+ months. Eleven of the 18 patients are still alive during the median follow-up time of 13 months. The median survival was 14+ months for complete responders, and 9.5 months for partial and nonresponders. A myelosuppressive toxicity was well tolerated. AVIP offers some hope as treatment of advanced non-Hodgkin's lymphoma.</p>
Keywords non-Hodgkin's lymphoma combination chemotherapy
Amo Type Article
Published Date 1982-02
Publication Title Acta Medica Okayama
Volume volume36
Issue issue1
Publisher Okayama University Medical School
Start Page 67
End Page 72
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 7064735
Web of Science KeyUT A1982NE20000007